CVT -

. Currency in USD
-
-
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters7 days ago

    Deals of the day-Mergers and acquisitions

    The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday: ** Shire, the London-listed rare diseases specialist that is a potential takeover target for Japan's Takeda Pharmaceutical, is selling its oncology business to unlisted French drugmaker Servier for $2.4 billion. ** Pebblebrook Hotel Trust has sweetened its $3 billion-plus offer to buy U.S. peer LaSalle Hotel Properties after the owner of high-end locations including 'W' Los Angeles saw an initial bid rebuffed last month.

  • Moody's6 months ago

    Cvent, Inc. -- Moody's affirms Cvent's B3 CFR, assigns B3 to sr sec term loan; outlook positive

    Rating Action: Moody's affirms Cvent's B3 CFR, assigns B3 to sr sec term loan; outlook positive. Global Credit Research- 03 Nov 2017. $700 million of new debt rated.

  • We're sorry this is all we were able to find about this topic.